Washington [US], November 6 (ANI): The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound developed by Hillhurst Biopharmaceuticals and already in early-stage trials for sickle cell disease, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.
\
\
